NKTR 192
Alternative Names: NKTR-192Latest Information Update: 23 Feb 2023
At a glance
- Originator Nektar Therapeutics
- Class Drug conjugates; Opioid analgesics
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute pain; Migraine
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Acute pain in USA (Parenteral) (Nektar Therapeutics pipeline, February 2023)
- 23 Feb 2023 Discontinued - Preclinical for Migraine in USA (Parenteral) (Nektar Therapeutics pipeline, February 2023)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Acute pain in USA (Parenteral, Injection)